Showing results (51-60 of 164) with videos related to
Sort By:
Pageof 17
JAMA Oncology|November 13, 2015
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung CancerJoseph McLaughlin, Gang Han, Kurt A Schalper, et al.Cancer Chemotherapy and Pharmacology|January 27, 2016
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumorsJason J Luke, Patricia LoRusso, Geoffrey I Shapiro, et al.British Journal of Cancer|September 2, 2020
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trialsJohnique T Atkins, Goldy C George, Kenneth Hess, et al.Cancer Research Communications|August 28, 2023
A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid TumorsMichael A Carducci, Ding Wang, Christina Habermehl, et al.The Oncologist|April 21, 2020
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid TumorsColin Weekes, Albert Lockhart, Patricia LoRusso, et al.American Journal of Clinical Oncology|October 7, 2006
A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancerLata Chandi Thatai, Priya Vishnubhotla, Laura Biernat, et al.Cancer Chemotherapy and Pharmacology|September 27, 2005
4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancersDavid Eilender, Patricia LoRusso, Leonard Thomas, et al.Investigational New Drugs|January 11, 2017
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumorsGeoffrey I Shapiro, Ulka N Vaishampayan, Patricia LoRusso, et al.Cancer Chemotherapy and Pharmacology|May 20, 2017
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairmentGhassan K Abou-Alfa, Lionel D Lewis, Patricia LoRusso, et al.Journal for Immunotherapy of Cancer|September 11, 2025
High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion propertiesJanie Yue Zhang, Barani Kumar Rajendran, Shruti S Desai, et al.Pageof 17